| The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts Experts in Chronic Myeloid Leukemia Blood, The Journal of the American Society of Hematology 121 (22), 4439-4442, 2013 | 657 | 2013 |
| Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back AF Alwan, BF Matti, AS Naji, AH Muhammed, MA Abdulsahib Leukemia & Lymphoma 55 (12), 2830-2834, 2014 | 25 | 2014 |
| Evaluation of the safety of imatinib mesylate in 200 Iraqi patients with chronic myeloid leukemia in the chronic phase: single-center study BF Matti, AF Alwan Turkish Journal of Hematology 30 (4), 387, 2013 | 23 | 2013 |
| Cytogenetic response in chronic myeloid leukaemia patients treated with imatinib mesylate homolog-drugs: 6 year’s transitional study N Khoshnaw, B Francis, BM Safar, SS Mahmood, BF Nore Journal of Cancer Therapy 2014, 2014 | 14 | 2014 |
| Treatment refractoriness in chronic lymphocytic leukemia: old and new molecular biomarkers N Maher, S Mouhssine, BF Matti, AF Alwan, G Gaidano International Journal of Molecular Sciences 24 (12), 10374, 2023 | 11 | 2023 |
| The efficacy of fludarabine, high dose cytosine arabinoside with granulocyte colony stimulating factor (FLAG) protocol as salvage therapy for refractory/relapsed acute … AF Alwan, BF Matti, AS Naji, AM Jawad Indian Journal of Hematology and Blood Transfusion 30, 231-235, 2014 | 11 | 2014 |
| Assessment of interleukin 1β serum level in different responder groups and stages of chronic myeloid leukemia patients on imatinb mesylate therapy BF Matti, MA Saleem, SF Sabir Indian Journal of Hematology and Blood Transfusion 30, 247-252, 2014 | 8 | 2014 |
| Molecular screening for T315I and F317L resistance mutations in Iraqi chronic myeloid leukemia non-responders patients to imatinib MAR Dhahi, BF Matti, S Fadel Cancer Clin Oncol 2 (2), 55-61, 2013 | 8 | 2013 |
| Neopterin And Interferon-Gamma as Immune Response Markers In Beta-Thalassemia Major Patients SF Obeid, SB AL-A’ARAJI, BF Matti, HA FAWZI Asian J Pharm Clin Res 11 (9), 192-194, 2018 | 6 | 2018 |
| Evaluation of electrolytes disturbances in Iraqi chronic myeloid leukemia patients treated with nilotinib with monitoring of response by FISH study BF Hasan, BF Matti, RY Hameed Baghdad Science Journal 12 (1), 110-118, 2015 | 4 | 2015 |
| Serum Calcium And Phosphateleveelsin Patients With Chronic Myeloid Leukemia Taking Different Dose of Tyrosine Kinase Inhibitors BF Matti, MAA Khaleq Al Mustansiriyah Journal of Pharmaceutical Sciences 17 (1), 9-9, 2017 | 3 | 2017 |
| Assessment of regulatory T cells (Tregs) and Foxp3 methylation level in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy SF Sabir, BF Matti, WMA Alwatar Immunogenetics 75 (2), 145-153, 2023 | 2 | 2023 |
| The role of miRNA-150 between different BCR-ABL p210 transcript levels and between different levels of imatinib optimal response in CML patients KA Radhi, BF Matti, IH Hamzah, R Alkasir Al-Mustansiriyah Journal of Science 34 (1), 16-22, 2023 | 2 | 2023 |
| Assessment of Serum Ferritin, Serum Calcium, and Vitamin D Status in β-thalassemia Major Children and Adolescents in Al Rusafa Side in Baghdad NB Jabbar, BM Ali, BF Matti Journal of Global Scientific Research 8 (10), 3298-3306, 2023 | 2 | 2023 |
| Treatment Outcomes of Nilotinib as Second Line Therapy for Chronic Myeloid Leukemia Patients in Karbala Province of Iraq A Mjali, MM Obaid, BF Matti, NT Abbas Asian Pacific Journal of Cancer Care 7 (2), 267-272, 2022 | 2 | 2022 |
| Characteristic of CD4+ CD25+ T Cells in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate with Different BCR-ABL Transcripts Levels Response. SF Sabir, WM Ali Alwatar, BF Matti Medico-Legal Update 21 (1), 2021 | 2 | 2021 |
| Hyper-CVAD protocol versus UKALL protocol and the minimal residual disease status in adult acute lymphoblastic leukemia patients A Mjali, BF Matti, YA Kareem, DA Hasan, A Alharganee, AF Alwan, ... Int J Med Res Health Sci 9 (10), 1-7, 2020 | 2 | 2020 |
| Treatment outcome of 100 chronic myeloid leukemia patients using nilotinib as the 2nd line therapy YM Taher, AM Almothaffar, BF Matti, AF Alwan Iraqi Journal of Hematology 7 (2), 67-71, 2018 | 2 | 2018 |
| Evaluation of Molecular Response to Imatinib in Iraqi Chronic Myeloid Leukemia Patients Using Real Time-Reveres Transcriptase-Polymerase Chain Reaction (RT-RT-PCR)-Taqman Assay MAR Dhahii, NS Murad, BF Matti Journal of Molecular Biology Research 1 (1), 47, 2011 | 2 | 2011 |
| The Role of Immune Check Point Gene Expression of Pd-1 and Tim-3 in Patients with Acute Myeloid Leukemia SM Oudah, IH Hamzah, BF Matti, R Alkasir Al-Mustansiriyah Journal of Science 35 (1), 27-32, 2024 | 1 | 2024 |
Alaa Fadhil AlwanProfessor of hematology在 uomustansiriyah.edu.iq 的电子邮件经过验证
